Most Chinese biotechnology stocks have been in a downward channel but not SSRX. This stock has been in an upward channel since last September, which means it moved more with the U.S. market rather than the Chinese pharmaceutical market over the past eight months. The stock saw strong volume come in all this week especially on Thursday in which SSRX almost reached a 52-week high. On Friday, Oppenheimer said the Chinese biotech/pharma space was a buying opportunity on recent weakness and outlined that buying should move first into the leader of the sector - that would be SSRX.
Click to enlarge
Price Target: $19.00
Support: $16.92
http://seekingalpha.com/article/265251-looking-ahead-to-the-trading-week-stocks-and-charts-to-watch?source=yahoo
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM